Amniotics AB (publ)’s Nomination Committee appointed for the Annual General Meeting (AGM) 2022
November 2, 2021
Amniotics AB (publ) hereby announces that the Nomination Committee for the AGM 2022 has been appointed.
In accordance with the instruction for the Nomination Committee, which was adopted by the AGM on April 15, 2021, the Nomination Committee shall consist of four members, one representative for each of the three largest shareholders on the last banking day in September and the Chairman of the board of directors. The “three largest shareholders” refers to the ownership grouped registered shareholders or in another way known shareholders as per the last banking day in September. Based on the above, the Nomination Committee for the AGM 2022 has been appointed and consists of:
- Christer Fåhraeus, representing Theope Seed Capital AB
- Marcus Larsson, representing Deflexum AB
- Fredrik Tiberg, representing LSCS Invest AB
- Peter Buhl Jensen, Chairman of the board of directors
Nomination Committee proposals
The Nomination Committee submits proposals to the AGM regarding inter alia the composition of the board of directors, remuneration to the board of directors, election of auditors and remuneration to the auditor.
Shareholders who wish to submit proposals to the Nomination Committee ahead of the AGM 2022 are welcome to contact the Nomination Committee no later than March 1, 2022.
by email to:
by regular mail to:
Amniotics AB (publ)
Attn: Nomination Committee
SE-223 63 Lund
For further information, please contact:
Peter Buhl Jensen, Chairman of the board, Amniotics AB
Phone: +45 21 60 89 22
Johny Humaloja, CFO, Amniotics AB
Phone: +46 (0) 735 06 68 56